课题基金 / 基金详情

PHASE I CHEMOPREVENTION OF PXM AND DFMO IN PREVIOUSLY TREATED SKIN CANCER

PHASE I CHEMOPREVENTION OF PXM AND DFMO IN PREVIOUSLY TREATED SKIN CANCER
PXM 和 DFMO 在既往治疗过的皮肤癌中的 I 期化学预防
批准号:
6282034
负责人:
PAUL P. CARBONE
金额:
$2.43万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 1998-11-30

项目摘要

项目成果

PAUL P. CARBONE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Carcinogenesis in many mammalian systems can be dissected into at least two qualitatively different steps, i.e. initiation and promotion. Interference with tumor promotion is an important target for designing successful chemoprevention studies. In a variety of model systems, tumor promotion is directly correlated with polyamine biosynthesis, especially putrescine. A rate limiting step in mammalian polyamine biosynthesis is ornithine decarboxylase (ODC) induction, and inhibition of ODC induction may be important in developing rational approaches to use of chemopreventive agents in humans. Prostaglandin (PG) inhibitors suppress tumor formation by blocking PG synthesis and ODC induction. The use of combinations of chemopreventive agents may yield an enhanced effect as well as decrease the possibility of toxicities. We propose to test the hypothesis that measuring levels of PG biosynthesis and ODC induction in tissues after oral administration of a presumptive chemopreventive agent may serve as intermediate endpoints as well as biomarkers to determine biologically effective doses of the agents for use in large scale prevention trials in humans. A two-step study is proposed to determine a safe and tolerable dose of piroxicam (PXM) alone and in combination with difluoromethylomithine (DFMO) which will inhibit prostaglandin and polyamine biosynthesis, important steps in tumor promotion. In Step 1, PXM, a potent long- acting prostaglandin synthesis inhibitor, will be studied for its ability to inhibit the 12-O-tetradecanoylphorbol-13-acetate (TPA) induction of ornithine decarboxylase in 3 mm skin biopsies and thromboxane B2 (TXB2) release from platelets. The second step will study PXM alone and in combination with DFMO, another human chemopreventive agent, on the same biological endpoints. In addition during both Steps 1 and 2, urinary decarboxylated S-adenosyl-L- methionine (dc-SAM), which is proposed to be correlated with ODC inhibition by DFMO, will be measured.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE
  • 批准号:
    6568834
  • 项目类别:
  • 资助金额:
    $10.66万
  • 财政年份:
    2001
  • 负责人:
    PAUL P. CARBONE
  • 依托单位:
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE
  • 批准号:
    6468957
  • 项目类别:
  • 资助金额:
    $10.66万
  • 财政年份:
    2000
  • 负责人:
    PAUL P. CARBONE
  • 依托单位:
CORE--DEVELOPMENTAL FUNDS
  • 批准号:
    6316507
  • 项目类别:
  • 资助金额:
    $28.96万
  • 财政年份:
    2000
  • 负责人:
    PAUL P. CARBONE
  • 依托单位:
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE
  • 批准号:
    6411640
  • 项目类别:
  • 资助金额:
    $1.29万
  • 财政年份:
    2000
  • 负责人:
    PAUL P. CARBONE
  • 依托单位:
海外基金